Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease

Detalles Bibliográficos
Autores principales: Patoulias, Dimitrios, Kalogirou, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2018
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300850/
https://www.ncbi.nlm.nih.gov/pubmed/30581509
http://dx.doi.org/10.5114/pg.2018.79815
_version_ 1783381754074103808
author Patoulias, Dimitrios
Kalogirou, Maria
author_facet Patoulias, Dimitrios
Kalogirou, Maria
author_sort Patoulias, Dimitrios
collection PubMed
description
format Online
Article
Text
id pubmed-6300850
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-63008502018-12-21 Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease Patoulias, Dimitrios Kalogirou, Maria Prz Gastroenterol Letter to the Editor Termedia Publishing House 2018-12-11 2018 /pmc/articles/PMC6300850/ /pubmed/30581509 http://dx.doi.org/10.5114/pg.2018.79815 Text en Copyright: © 2018 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Letter to the Editor
Patoulias, Dimitrios
Kalogirou, Maria
Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
title Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
title_full Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
title_fullStr Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
title_full_unstemmed Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
title_short Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
title_sort empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300850/
https://www.ncbi.nlm.nih.gov/pubmed/30581509
http://dx.doi.org/10.5114/pg.2018.79815
work_keys_str_mv AT patouliasdimitrios empagliflozinpromisestobridgethegapbetweennonalcoholicfattyliverdiseasetype2diabetesandcardiovasculardisease
AT kalogiroumaria empagliflozinpromisestobridgethegapbetweennonalcoholicfattyliverdiseasetype2diabetesandcardiovasculardisease

Ejemplares similares